Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915799 | 0.84 | P2RX7 (0.51) | P2RX7CYP1A2GRM5MEN1KMT2A | |
| SCHEMBL5752974 | 0.84 | CYP1A2 (0.50) | CYP1A2MEN1KMT2AMGAMGAA | |
| SCHEMBL18593230 | 0.84 | CYP1A2 (0.50) | P2RX7CYP1A2MEN1KMT2AMGAM | |
| SCHEMBL1545927 | 0.84 | CYP1A2 (0.63) | CYP1A2GRM5MEN1KMT2AMGAM | |
| SCHEMBL5751063 | 0.84 | CYP1A2 (0.50) | P2RX7CYP1A2MEN1KMT2AMGAM | |
| SCHEMBL24141795 | 0.84 | CYP1A2 (0.50) | CYP1A2GRM5MEN1KMT2AMGAM | |
| SCHEMBL15661105 | 0.83 | CYP1A2 (0.49) | CYP1A2GRM5MEN1KMT2AMGAM | |
| SCHEMBL20028746 | 0.81 | P2RX7 (0.55) | P2RX7CYP1A2GRM5KMT2AMAPT | |
| SCHEMBL1460111 | 0.80 | KMT2A (0.57) | MEN1KMT2AMGAMGAAMAPT | |
| SCHEMBL19806454 | 0.80 | P2RX7 (0.57) | P2RX7CYP1A2GRM5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215017-A1 | TGF-ß INHIBITOR COMPOUND AND USE THEROF | MEDINNO PHARMACEUTICAL TECHNOLOGY (ZHUHAI) CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| US-20250179094-A1 | TGF-B INHIBITOR COMPOUND AND USE THEREOF | MEDINNO PHARMACEUTICAL TECHNOLOGY (ZHUHAI) CO., LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-4556478-A1 | TGF-BETA INHIBITOR COMPOUND AND USE THEREOF | Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| EP-4556477-A1 | TGF-BETA INHIBITOR COMPOUND AND USE THEREOF | Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| CN-117534686-A | TGF-beta inhibitor compounds and uses thereof | 河南迈英诺医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117534675-A | TGF-beta inhibitor compounds and uses thereof | 河南迈英诺医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-113620956-B | Transforming growth factor receptor antagonist, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2022076905-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076905-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11236112-B2 | Crystal form and salt form of TGF-βRI inhibitor and preparation method therefor | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20070155722-A1 | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155722-A1 | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1723146-A1 | FUSED PYRAZOLE DERIVATIVES AS TGF-BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF FIBROSIS AND NEOPLASMS | ELI LILLY AND COMPANY (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006052568-A2 | TGF-BETA INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| WO-2005092894-A1 | FUSED PYRAZOLE DERIVATIVES AS TGF-BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF FIBROSIS AND NEOPLASMS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
| EP-1567528-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004048383-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179094-A1 | TGF-B INHIBITOR COMPOUND AND USE THEREOF | TGFB1, TGFB2, TGFBR1 | P2RX7 3502/4885CYP1A2 2051/4885GRM5 3478/4885 |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | P2RX7 2979/4885CYP1A2 3740/4885GRM5 3565/4885 |
| US-20070155722-A1 | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms | SMAD3, TGFBR1, TGFBR2 | P2RX7 2870/4885CYP1A2 2583/4885GRM5 3371/4885 |
| US-11236112-B2 | Crystal form and salt form of TGF-βRI inhibitor and preparation method therefor | TGFBR1, TGFBR2, TGFB1 | P2RX7 3791/4885CYP1A2 4691/4885GRM5 2500/4885 |
| US-20250215017-A1 | TGF-ß INHIBITOR COMPOUND AND USE THEROF | TGFB1, TGFB2, TGFBR2 | P2RX7 3750/4885CYP1A2 3248/4885GRM5 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.